ATE219670T1 - Verwendung von arachidonsäure und/oder docohexaensäure zur herstellung eines arzneimittels zur behandlung von dyspraxia - Google Patents
Verwendung von arachidonsäure und/oder docohexaensäure zur herstellung eines arzneimittels zur behandlung von dyspraxiaInfo
- Publication number
- ATE219670T1 ATE219670T1 AT97937714T AT97937714T ATE219670T1 AT E219670 T1 ATE219670 T1 AT E219670T1 AT 97937714 T AT97937714 T AT 97937714T AT 97937714 T AT97937714 T AT 97937714T AT E219670 T1 ATE219670 T1 AT E219670T1
- Authority
- AT
- Austria
- Prior art keywords
- acid
- dyspraxia
- treatment
- docohexaene
- production
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fats And Perfumes (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9617847.0A GB9617847D0 (en) | 1996-08-27 | 1996-08-27 | Fatty acid treatment |
PCT/GB1997/002282 WO1998008501A1 (en) | 1996-08-27 | 1997-08-26 | Use of arachidonic acid and/or docosahexanoic acid for the manufacture of a medicament for the treatment of dyspraxia |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE219670T1 true ATE219670T1 (de) | 2002-07-15 |
Family
ID=10798969
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT97937714T ATE219670T1 (de) | 1996-08-27 | 1997-08-26 | Verwendung von arachidonsäure und/oder docohexaensäure zur herstellung eines arzneimittels zur behandlung von dyspraxia |
Country Status (14)
Country | Link |
---|---|
US (1) | US6184251B1 (de) |
EP (1) | EP0956011B1 (de) |
JP (1) | JP2001504086A (de) |
KR (1) | KR20000035924A (de) |
AT (1) | ATE219670T1 (de) |
AU (1) | AU738117B2 (de) |
CA (1) | CA2263839A1 (de) |
DE (1) | DE69713620D1 (de) |
GB (1) | GB9617847D0 (de) |
IL (1) | IL128562A0 (de) |
NO (1) | NO990934L (de) |
NZ (1) | NZ334260A (de) |
WO (1) | WO1998008501A1 (de) |
ZA (1) | ZA977686B (de) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6258846B1 (en) * | 1999-06-01 | 2001-07-10 | Drugtech Corporation | Nutritional supplements |
GB0016045D0 (en) * | 2000-06-29 | 2000-08-23 | Laxdale Limited | Therapeutic combinations of fatty acids |
JP2003048831A (ja) | 2001-08-02 | 2003-02-21 | Suntory Ltd | 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物 |
CN101843610A (zh) * | 2003-03-27 | 2010-09-29 | 三得利控股株式会社 | 花生四烯酸在制备具有使超昼夜节律正常化作用的组合物中的用途 |
GB0311081D0 (en) | 2003-05-14 | 2003-06-18 | Btg Internat Limted | Treatment of neurodegenerative conditions |
DE112004001520B4 (de) * | 2003-08-18 | 2008-04-10 | Btg International Ltd. | Verwendung eines Lipidglyzerids festgelegter Struktur zur Herstellung eines Medikamentes zur Behandlung der multiplen Sklerose |
WO2005046668A1 (ja) * | 2003-11-14 | 2005-05-26 | Mochida Pharmaceutical Co., Ltd. | 言語障害予防・治療剤 |
US20090215896A1 (en) * | 2004-01-19 | 2009-08-27 | Martek Biosciences Corporation | Reelin deficiency or dysfunction and methods related thereto |
GB0425932D0 (en) * | 2004-11-25 | 2004-12-29 | Btg Int Ltd | Structured phospholipids |
GB0504333D0 (en) * | 2005-03-02 | 2005-04-06 | Btg Int Ltd | Treatment of cytokine dysregulation |
GB0504362D0 (en) * | 2005-03-02 | 2005-04-06 | Btg Int Ltd | Cytokine modulators |
JP5967855B2 (ja) | 2005-06-30 | 2016-08-10 | サントリーホールディングス株式会社 | 日中活動量の低下および/又はうつ症状の改善作用を有する組成物 |
US20070166411A1 (en) * | 2005-12-16 | 2007-07-19 | Bristol-Myers Squibb Company | Nutritional supplement containing long-chain polyunsaturated fatty acids |
EP2131679B1 (de) * | 2007-02-22 | 2019-03-27 | Children's Hospital & Research Center at Oakland | Fettsäureformulierungen und verwendungsverfahren dafür |
CA2704371A1 (en) * | 2007-11-01 | 2009-05-07 | Wake Forest University School Of Medicine | Compositions and methods for prevention and treatment of mammalian diseases |
US8343753B2 (en) * | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
GB2460056A (en) * | 2008-05-14 | 2009-11-18 | Arab Science & Technology Foun | Compositions comprising omega-6 fatty acids for use in treating schistosomiasis |
US8715648B2 (en) | 2011-02-16 | 2014-05-06 | Pivotal Therapeutics Inc. | Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics |
US9119826B2 (en) | 2011-02-16 | 2015-09-01 | Pivotal Therapeutics, Inc. | Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels |
US8952000B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events |
US8951514B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4595985A (en) | 1984-08-10 | 1986-02-13 | Sentrachem Limited | Cancer treatment |
GB8813766D0 (en) | 1988-06-10 | 1988-07-13 | Efamol Holdings | Essential fatty acid compositions |
FR2653972B1 (fr) | 1989-11-07 | 1993-07-09 | Perrier Sante Sa | Phase grasse pour produits alimentaires et matieres alimentaires comparables a la creme contenant ladite phase grasse et leur procede de preparation. |
GB9026648D0 (en) | 1990-12-07 | 1991-01-23 | Efamol Holdings | Nutrition |
GB9217780D0 (en) | 1992-08-21 | 1992-10-07 | Efamol Holdings | Fatty acid treatment |
GB9217781D0 (en) | 1992-08-21 | 1992-10-07 | Efamol Holdings | Fatty acid treatment |
DE4304394A1 (en) | 1993-02-13 | 1993-09-02 | Fresenius Ag | Prepn. for nourishment of oncological patients - comprises fats formulation contg. oleic acid, alpha-linolenic acid, etc., and opt. carbohydrate and proteins |
CA2119000A1 (en) | 1993-03-19 | 1994-09-20 | David Frederick Horrobin | Formulation for use in smokers |
CA2164291C (en) | 1993-06-09 | 2007-10-30 | David John Kyle | Methods and pharmaceutical compositions useful for treating neurological disorders |
GB9423625D0 (en) | 1994-11-23 | 1995-01-11 | Scotia Holdings Plc | Fortified fruit juice |
-
1996
- 1996-08-27 GB GBGB9617847.0A patent/GB9617847D0/en active Pending
-
1997
- 1997-08-26 US US09/254,074 patent/US6184251B1/en not_active Expired - Fee Related
- 1997-08-26 IL IL12856297A patent/IL128562A0/xx unknown
- 1997-08-26 KR KR1019997001660A patent/KR20000035924A/ko not_active Application Discontinuation
- 1997-08-26 CA CA002263839A patent/CA2263839A1/en not_active Abandoned
- 1997-08-26 EP EP97937714A patent/EP0956011B1/de not_active Expired - Lifetime
- 1997-08-26 AT AT97937714T patent/ATE219670T1/de not_active IP Right Cessation
- 1997-08-26 WO PCT/GB1997/002282 patent/WO1998008501A1/en not_active Application Discontinuation
- 1997-08-26 NZ NZ334260A patent/NZ334260A/xx unknown
- 1997-08-26 JP JP51136998A patent/JP2001504086A/ja not_active Ceased
- 1997-08-26 DE DE69713620T patent/DE69713620D1/de not_active Expired - Lifetime
- 1997-08-26 AU AU40247/97A patent/AU738117B2/en not_active Ceased
- 1997-08-27 ZA ZA9707686A patent/ZA977686B/xx unknown
-
1999
- 1999-02-26 NO NO990934A patent/NO990934L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO1998008501A1 (en) | 1998-03-05 |
AU738117B2 (en) | 2001-09-06 |
NO990934D0 (no) | 1999-02-26 |
EP0956011A1 (de) | 1999-11-17 |
IL128562A0 (en) | 2000-01-31 |
CA2263839A1 (en) | 1998-03-05 |
ZA977686B (en) | 1998-02-27 |
AU4024797A (en) | 1998-03-19 |
NZ334260A (en) | 2000-08-25 |
US6184251B1 (en) | 2001-02-06 |
KR20000035924A (ko) | 2000-06-26 |
DE69713620D1 (de) | 2002-08-01 |
JP2001504086A (ja) | 2001-03-27 |
GB9617847D0 (en) | 1996-10-09 |
EP0956011B1 (de) | 2002-06-26 |
NO990934L (no) | 1999-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE219670T1 (de) | Verwendung von arachidonsäure und/oder docohexaensäure zur herstellung eines arzneimittels zur behandlung von dyspraxia | |
ATE231885T1 (de) | Verwendung von komplement-inhibitoren zur herstellung eines arzneimittels zur prophylaxe und therapie von entzündlichen darm- und hauterkrankungen sowie purpura | |
ATE332702T1 (de) | Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen | |
ATE205086T1 (de) | Verwendung von dem chelatbildner clioquinol zur herstellung eines arzneimittelszur behandlung von alzheimerschen krankheit | |
ATE330593T1 (de) | Verwendung von topiramat oder derivate davon zur herstellung eines arzneimittels zur behandlung von manisch-depressiven bipolaren störungen | |
ATE204704T1 (de) | Verwendung von bcl-2 zur herstellung von arzneimitteln zur therapeutischen behandlung und verhinderung von krankheiten | |
ATE116848T1 (de) | Verwendung von baclofen zur herstellung von arzneimitteln zur behandlung von angina pectoris. | |
ATE249828T1 (de) | Verwendung von isatin- und oxindolderivaten zur herstellung von arzeneimittel für die behandlung von mykobakteriellen erkrankungen | |
ATE269077T1 (de) | Verwendung von tetrahydropyridinderivaten zur herstellung von arzneimitteln zur behandlung demyelinisierender erkrankungen | |
DE3583220D1 (de) | Verwendung von dipeptidderivaten fuer die herstellung von arzneimitteln zur behandlung von an amyotropher lateralsklerose erkrankten. | |
DE69921662D1 (de) | Verwendung von gingko biloba extrakten zur herstellung eines arzneimittels zur behandlung der amyotrophen lateralsklerose | |
ATE274349T1 (de) | Verwendung von fruktan zur herstellung eines arzneimittels zur vorbeugung und behandlung von dickdarmkrebs | |
DE69635298D1 (de) | Verwendung von Acetylsalicylsäuren zur Herstellung eines Medikaments für die Behandlung von Hautverletzungen | |
DE69130679T2 (de) | Die herstellung von zusammensetzungen zur behandlung von krankheiten der zellproliferation | |
ATE217191T1 (de) | Verwendung von phanquinon zur behandlung von alzheimer's krankheit | |
ATE309817T1 (de) | Pharmazeutische zusammensetzung die trkaig2 enthält zur verwendung in der vorbeugung und/oder behandlung von krebs | |
DE3781054D1 (de) | Die verwendung von d-fenfluramin zur herstellung von arzneimitteln, zur behandlung von depressionen. | |
ATE192929T1 (de) | Verwendung von dimeticon zur herstellung eines arzneimittels zur behandlung von aphthen und stomatitis | |
ATE234613T1 (de) | Verwendung von comt inhibitoren zur herstellung eines arzneimittels zur vorbeugung von diabetischen vaskulären funktionsstörungen | |
DE69630055D1 (de) | Verwendung von olanzapin oder eines salzes für die herstellung eines medikaments für die behandlung von autismus und mentaler retardation | |
ATE192650T1 (de) | Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit | |
DE3578374D1 (de) | Verwendung von chinolonen fuer die herstellung eines arzneimittels zur behandlung von herzerkrankungen. | |
DE69610045T2 (de) | Verwendung eines Rohpflanzenextraktes zur Herstellung eines Arzneimittels zur Behandlung von HIV-Infektionen | |
ATE186640T1 (de) | Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung neurogenerativer erkrankungen | |
ATE229343T1 (de) | Kombination von temozolomide und alpha-interferon zur behandlung von fortgeschrittenem krebs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |